1Dipartimento materno-infantile, Ospedale S. Giovanni di Dio, Azienda per i Servizi sanitari n° 2 Isontina, Gorizia
2SOS Malattie emorragiche e trombotiche, Azienda Ospedaliera Universitaria “S. Maria della Misericordia”, Udine
Indirizzo per corrispondenza: email@example.com
Key words: Haemophilia, Inhibitors development, Prophylaxis, Quality of life
Haemophilia A and B are X-linked inherited bleeding disorders, characterized by a posttraumatic or spontaneous high tendency to bleeding and whose severity correlates with plasma levels of a specific coagulative factor. In therapeutic terms remarkable changes have been made about the greater availability of the missing factor (derived plasma and recombinant factor), so the effects of bleeding and formation of the haemarthroses can be reduced by adding the factor periodically in relation to the individual needs. One problem regarding the formation of antibodies that make the treatment ineffective still remains open.
Vuoi citare questo contributo?